Pulmicort (budesonide) is an inhaled anti-inflammatory glucocorticosteroid for initiation and maintenance treatment of bronchial asthma in infants, children and adults. In some countries Pulmicort is also indicated for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Pulmicort is available in a range of formulations: Pulmicort Turbuhaler (dry powder inhaler), Pulmicort pMDI (pressurised metered dose inhaler), and Pulmicort Respules (suspension for nebulisation). Trade names and availability of formulations may differ between countries.
Did you know?
AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.
Links to country-specific websites can be found using the AstraZeneca websites list.
If you still have a question regarding our drug portfolio you can Contact us.
Not signed in
Page tools
Share price
- London
-
27.02 GBP - New York
-
44.93 USD - Stockholm
-
314.10 SEK
At 05-Nov-2009 21:45 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
